Results 251 to 260 of about 213,470 (338)

Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Obesity, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP‐1s) are shifting the treatment landscape for obesity. However, real‐world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP‐1 efficacy, equitable results, and ...
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa Sannidhi, Fatima Cody Stanford, Emily A. Callahan   +17 more
wiley   +1 more source

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. [PDF]

Diabetes Ther
Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E.   +4 more
europepmc   +1 more source

Grip strength: are some adiposity phenotypes more detrimental than others? A Mendelian randomization study

Obesity, EarlyView.
Abstract Objective Our objective was to investigate causal associations of adiposity in different locations and metabolically favorable and unfavorable adiposity (MetFA and MetUFA, respectively) with grip strength. Methods Observational cross‐sectional and Mendelian randomization (MR) (sex combined and stratified) analysis within UK Biobank (N ≤ 340 ...
Amy E. Taylor, John Vincent, Dylan M. Williams, Rachel Cooper, Snehal M. Pinto Pereira   +4 more
wiley   +1 more source

Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Glycated hemoglobin (HbA1c) is the gold standard for measuring long‐term glycemic efficacy over at least 3 months in Type 2 diabetes (T2D). Being able to predict HbA1c using glucose response from studies of less than 3 months would be useful.
Austin Yue Feng Tan, Karen Schneck, Parag Garhyan, Eric Chun Yong Chan, Lai San Tham   +4 more
wiley   +1 more source

Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event. [PDF]

Endocrinol Diabetes Metab Case Rep
Weschle L, Potratz J, Rutsch F, Humberg A, Oesingmann S, Pascher A, Busch AS, Masjosthusmann K.   +7 more
europepmc   +1 more source

Tests on Three Antisera und Subsequent Development of Radioimmunoassay for Different Regions of Human parathyrin [PDF]

, 1979
Marschner, I., Scriba, Peter Christian, Wood, W. G.   +2 more
core  

Effect of Splanchnic Nerve Stimulation on Glucagon and Insulin Secretion

, 1973
AKIO KANETO, Hiroshi Kajinuma, Masaki Hayashi, Kinori Kosáka   +3 more
openalex   +2 more sources

From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
A combined systems model (4GI‐HbA1c) was developed to predict glucose and HbA1c responses to GLP‐1 and GLP‐1/glucagon receptor agonists using early pharmacokinetic and in vitro efficacy data. Validated with short‐term CGM data, the model accurately predicted 26‐week clinical outcomes for liraglutide and cotadutide, demonstrating its value in supporting
Rolien Bosch, Marcella Petrone, Rosalin Arends, Eric J. G. Sijbrands, Sven Hoefman, Nelleke Snelder   +5 more
wiley   +1 more source

Acute Inhibition of Adipose Triglyceride Lipase by NG497 Dysregulates Insulin and Glucagon Secretion From Human Islets.

Endocrinology
Kim LB, Liu S, Richtsmeier S, Górniak M, Vikram A, Imai Y.   +5 more
europepmc   +1 more source